A. S. Lapina

A. S. Lapina

Auto-generated profile, based on publicly available information

A. S. Lapina

Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2018 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
AKAlexander Kulagin
Alexander Kulagin
OKO. U. Klimova
O. U. Klimova
ADA. V. Dobronravov
A. V. Dobronravov
TRT. A. Rudakova
T. A. Rudakova
IGI. K. Golubovskaya
I. K. Golubovskaya
BAB. V. Afanasyev
B. V. Afanasyev
Пароксизмальная ночная гемоглобинурия у детей и взрослых: сравнительный клинический профиль и долгосрочный прогноз

22 November 2020 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Open access
PDF file
NDN. S. Demikova
N. S. Demikova
ALA. S. Lapina
A. S. Lapina
MPM. A. Podolnaya
M. A. Podolnaya
APA. N. Putintsev
A. N. Putintsev
Значение генетических исследований в изучении природы врожденных пороков развития

15 May 2020 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Open access
PDF file
NDN. S. Demikova
N. S. Demikova
MPM. А. Podolnaya
M. А. Podolnaya
ALA. S. Lapina
A. S. Lapina
Objective. To analyze the age structure of the mothers of children with birth defects and to assess the age-related risks of chromosomal and non-chromosomal congenital anomalies.Material and methods. The authors analyzed the data from 23 regional registers of birth defects from 2011 to 2018. There were total 5 047 468 births during this period. The authors calculated the incidence and relative risks of chromosomal and non-chromosomal birth defects in different age groups of mothers: under 20, from 20 to 34, from 35 to 39, 40–44, and above 45 years old.Results. The incidence of chromosomal abnormalities significantly increases with the mother’s age. The relative risk (RR) of chromosomal abnormalities in different age groups: 4,67 (95% CI 4,44–4,92) in Group 35-39, 15,00 (95% CI 14,10–15,96) in Group 40–44, and 26,49 (95% CI 21,89–32,07) in Group ≥45 as compared with the main age group of 20–34 years old. The authors also revealed the dependence of the non-chromosomal birth defects on the age of the mother: RR 1,15 (95% CI 1,08–1,23) in Group <20 years, RR 1,18 (95% CI 1,13–1,23) in Group 35–39, RR 1,35 (95% CI 1,24–1,47) in Group 40–44, and RR 2,03 (95% CI 1,47–2,79) in Group ≥ 45 years old.Conclusion. The study demonstrates the dependence of chromosomal and non-chromosomal birth defects on the mother’s age.

16 January 2020 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Open access
PDF file
NDN. S. Demikova
N. S. Demikova
MPM. A. Podolnaya
M. A. Podolnaya
ALA. S. Lapina
A. S. Lapina
Neural tube defects – a group of severe congenital malformations with a high level of mortality, childhood disability. The average prevalence of these defects is approximately 1 per 1000 births. The main measures to reduce the prevalence of neural tube defects are primary and secondary prevention measures, the effectiveness of which can be determined by congenital malformations monitoring.Research purpose. To determine the prevalence of neural tube defects, as well as trends in their prevalence for 2011 to 2017 in the Russian Federation according to monitoring of congenital malformations.Results. The total prevalence of anencephaly among newborns and fetuses was 4.63 (95% confidence interval - CI 4.40–4.88) per 10000 births, spina bifida – 6.18 (95% CI 5.91–6.46) and encephalocele 1.34 (95% CI 1.21–1.47). At the same time, the prevalence of anencephaly only among live births was 0.11 (95% CI 0.08–0.15) per 10000, spina bifida – 2.24 (95% CI 2.08–2.41) and encephalocele – 0 25 (95% CI 0.20–0.31). The decrease in prevalence of birth defects among live births compared with the total prevalence is provided by a high level of detection of these defects by ultrasound examination during pregnancy with the subsequent elimination of the affected fetuses. The maximum proportion of eliminated fetuses is observed for anencephaly (90.5%), for encephalocele the proportion of aborted fetuses is 77.4% and for spina bifida – 59.3%. Over the 7-year period, the multidirectional prevalence trends were noted: the increasing trend for total prevalence of neural tube defects and the decreasing trend for prevalence of these defects among live-born children.Conclusion. Estimates of the prevalence of neural tube defects in Russian Federation regions are obtained. The dynamics of the studied defects prevalence indicates that the decreasing of neural tube defects prevalence among live births is associated with secondary prevention measures.

1 September 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
MMM. V. Marchenko
M. V. Marchenko
OKO. U. Klimova
O. U. Klimova
EAE. V. Anikina
E. V. Anikina
ALA. V. Lapina
A. V. Lapina
TRT. A. Rudakova
T. A. Rudakova
AKAlexander Kulagin
Alexander Kulagin
The introduction of the complement component C5 inhibitor eculizumab has radically changed the prognosis and quality of life of patients with paroxysmal nocturnal hemoglobinuria. Up to 30 % of patients develop only a suboptimal response to C5 inhibition. One reason for this is activation of extravascular hemolysis, due to opsonization of erythrocytes with fragments of the C3 component. Pegcetacoplan, the first ever registered C3 inhibitor, is aimed at solving this problem.In Russia, 2 patients received pegcetacoplan as part of a phase 3, randomized, open-label, active-comparator controlled trial PEGASUS. The analysis includes data from the first year of therapy: the run-in period (pegcetacoplan 1080 mg SC twice weekly in addition to the current dose of eculizumab, 4 weeks), the randomized controlled period (both patients were randomized to eculizumab monotherapy, 16 weeks), and the open-label period of pegcetacoplan therapy (32 weeks). Data from the extension study to evaluate the long-term safety and efficacy of pegcetacoplan are also presented. The duration of follow-up on pegcetacoplan therapy in both patients exceeded 4 years.